Award notice observed
Latest variant observed by Bidwake on .
Open this official Contracts Finder notice
Record references
- Release reference
c5870a3f-91ee-4056-b444-6ea461521a27-122513- Published tags
- award
Loading records…
Public procurement
See the published facts, notice history, awards and supplier links in one place. Open the original Contracts Finder notice for the full record.
ocds-b5fd17-06fa79dc-259f-4c60-9146-15668762fd7aPublished facts
c5870a3f-91ee-4056-b444-6ea461521a27-122513NGHT has had to publish a VEAT notice for the following therapy: Xofigo (Radium 223) Dose. The reason for the VEAT notice was due to: "There was a palliative treatment called Strontium that could be used for bone pain, however this involved some significant side-effects and hence it has not been used for a number of years. This new treatment (Radium 223) has been shown to significantly improve overall survival for this group of patients. (ALSYMPCA trial). Currently these patients are either sent elsewhere for the same treatment, or they do not receive treatment. This is the only radiopharmaceutical that has been granted NICE approval for treatment of bone metastasis, and is the only Radium (223) product currently available commercially.
Observed notice trail
Events follow the publisher date where one is available. “Seen by Bidwake” is the date this service first found the record.
Award notice observed
Latest variant observed by Bidwake on .
Open this official Contracts Finder notice
c5870a3f-91ee-4056-b444-6ea461521a27-122513Awards and suppliers
Buyer: Northampton General Hospital N H S TrustSupplier: Bayer PLC
ocds-b5fd17-06fa79dc-259f-4c60-9146-15668762fd7a-1End dates, recurrence wording and links are shown as they appear in public notices. They do not create a new opportunity. If no later linked record appears here, that means Bidwake did not find one in the records it has loaded; it does not prove that none exists.